Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation
Cancer/Radiothérapie · 2024
DOI: 10.1016/j.canrad.2024.09.002 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer/Radiothérapie, 2024. Verfasst von Arnaud Beddok und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, institut Godinot, Reims, France; Université de Reims Champagne-Ardenne, Crestic, Reims, France; Yale PET Center, De…. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Re-Irradiation, Precision Medicine, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: This review systematically investigates the role of radiomics in radiotherapy, with a particular emphasis on the use of quantitative imaging biomarkers for predicting clinical outcomes, assessing toxicity, and optimizing treatment planning. While the review encompasses various applications of radiomics in radiotherapy, it particularly highlights its potential for guiding reirradiation of recurrent cancers. METHODS: A systematic review was conducted based on a Medline search with the search engine PubMed using the keywords "radiomics or radiomic" and "radiotherapy or reirradiation". Out of 189 abstracts reviewed, 147 original articles were included in the analysis. These studies were categorized by tumor localization, imaging modality, study objectives, and performance metrics, with a particular emphasis on the inclusion of external validation and adherence to a standardized radiomics pipeline. RESULTS: The review identified 14 tumor localizations, with the majority of studies focusing on lung (33 studies), head and neck (27 studies), and brain (15 studies) cancers. CT was the most frequently employed imaging modality (77 studies) for radiomics, followed by MRI (46 studies) and PET (13 studies). The overall AUC across all studies, primarily focused on predicting the risk of recurrence (94 studies) or toxicity (41 studies), was 0.80 (SD=0.08). However, only 24 studies (16.3%) included external validation, with a slightly lower AUC compared to those without it. For studies using CT versus MRI or PET, both had a median AUC of 0.79, with IQRs of 0.73-0.86 for CT and 0.76-0.855 for MRI/PET, showing no significant differences in performance. Five studies involving reirradiation reported a median AUC of 0.81 (IQR: 0.73-0.825). CONCLUSION: Radiomics demonstrates considerable potential in personalizing radiotherapy by improving treatment precision through better outcome prediction and treatment planning. However, its clinical adoption is hindered by the lack of external validation and variability in study designs. Future research should focus on implementing rigorous validation methods and standardizing imaging protocols to enhance the reliability and generalizability of radiomics in clinical radiotherapy, with particular attention to its application in reirradiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, institut Godinot, Reims, France; Université de Reims Champagne-Ardenne, Crestic, Reims, France; Yale PET Center, Department of Radiology & Biomedical Imaging, Yale University School of…
- Institut Curie, université PSL, université Paris Saclay, Inserm Lito U1288, Orsay, France.
- Yale PET Center, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, USA; Department of Nuclear Medicine, hôpitaux universitaires la Pitié Salpêtrière-Charles-Foix,…
- Institut Curie, université PSL, université Paris Saclay, Inserm Lito U1288, Orsay, France; Department of Radiation Oncology, institut Curie, université PSL, Paris, France.
- Department of Radiology, New York-Presbyterian Hospital, Columbia University, Vagelos College of Physicians and Surgeons, New York, USA.
- Department of Radiation Oncology, centre François-Baclesse, Caen, France.
Zitieren
APA
Beddok, A., Orlhac, F., Rozenblum, L., Calugaru, V., Créhange, G., Dercle, L., Nioche, C., Thariat, J., Marin, T., El Fakhri, G., & Buvat, I. (2024). Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2024.09.002
Vancouver
Beddok A, Orlhac F, Rozenblum L, Calugaru V, Créhange G, Dercle L, et al. Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation. Cancer/Radiothérapie. 2024. doi:10.1016/j.canrad.2024.09.002
BibTeX
@article{Beddok2024,
author = {Beddok, Arnaud and Orlhac, Fanny and Rozenblum, Laura and Calugaru, Valentin and Créhange, Gilles and Dercle, Laurent and Nioche, Christophe and Thariat, Juliette and Marin, Thibault and El Fakhri, Georges and Buvat, Irène},
title = {Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation},
journal = {Cancer/Radiothérapie},
year = {2024},
doi = {10.1016/j.canrad.2024.09.002}
}
EUVIMED